Epilepsy Market would rocket up to USD 3,888.27 million by 2030

Published October 25, 2023

Data Bridge Market research has a newly released expansive study titled “Epilepsy Market” which guarantees you will remain better informed than your competition. This study provides a broader perspective of the marketplace with its comprehensive market insights and analysis which eases survival and succeeding in the market. A complete overview of the industry has been presented via this Intercom Devices report which considers various aspects of product definition, market segmentation, and the existing retailer landscape.

Epilepsy is a neurological disorder characterized by recurrent, unprovoked seizures. Seizures occur due to abnormal electrical activity in the brain, which leads to temporary disruptions in normal brain function. Epilepsy can affect people of all ages, and its causes can vary. If someone experiences recurring seizures, they should seek medical attention. A diagnosis of epilepsy typically involves a thorough medical history review, neurological examination, and various tests, such as electroencephalogram (EEG), brain imaging (MRI, CT scan), and blood tests. These help identify the underlying cause and determine the most appropriate treatment.

Data Bridge Market Research analyses that the epilepsy market which was USD 2,280.00 million in 2022, would rocket up to USD 3,888.27 million by 2030, and is expected to undergo a CAGR of 6.9% during the forecast period. Epilepsy drug resistant/intractable epilepsy dominates the product type segment of the Epilepsy market owing to the increasing prevalence of epilepsy. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Request a Sample PDF:  https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-epilepsy-market&Shri

The term “epilepsy” describes a long-term neurological condition that results in frequent, unjustified seizures. A person with epilepsy frequently experiences seizures that have no known cause. The actual origins of these seizures are unknown, but some stressful event or a prior brain injury may bring them. The disorder often affects both adults and children, however, the danger of infection is higher in the elderly population.


  • Pediatric epilepsy treatment market

Pediatric epilepsy represents a significant segment of the overall epilepsy market. The rising prevalence of epilepsy in children and the development of pediatric-specific AEDs fuel market growth. Additionally, initiatives focused on improving pediatric epilepsy care and advancing research contribute to market expansion.

  • Awareness campaigns and patient advocacy

Various organizations and advocacy groups dedicated to epilepsy awareness and support play a crucial role in driving market growth. These campaigns aim to reduce the stigma associated with epilepsy, improve early detection, and ensure access to proper treatment and support services.


  • Side effects of antiepileptic drugs (AEDs)

Although AEDs are essential in managing epilepsy, they can have significant side effects, such as drowsiness, dizziness, cognitive impairments, and mood changes. These side effects can impact patient compliance with medication regimens and lead to treatment discontinuation, affecting the overall market growth.

  • Limited efficacy of current treatments

Despite the availability of a wide range of AEDs, a considerable number of patients with epilepsy experience inadequate seizure control or drug resistance. This limitation in treatment efficacy underscores the need for more effective therapeutic options and personalized treatment approaches, which may impact the market growth.

This epilepsy market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the epilepsy market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Development

  • In March 2022, FDA has approved Ztalmy (ganaxolone) to treat seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) in patients 2 years of age and older. This is the first treatment for seizures associated with CDD and the first treatment specifically for CDD.
  • In January 2021, Glenmark Pharma announced the launch of the anti-epileptic drug Rufinamide tablets in the US market. Glenmark Pharmaceuticals Ltd has launched Rufinamide tablets USP in 200 mg and 400 mg, the company said in a regulatory filing.

Explore the Full Report:  https://www.databridgemarketresearch.com/reports/global-epilepsy-market?Shri

Some of the major players operating in the epilepsy market are:

  • Pfizer Inc. (U.S.)
  • Novartis AG (Germany)
  • Abbott (U.S.)
  • Neurelis Inc. (U.S.)
  • GSK plc (U.K.)
  • Johnson & Johnson Services Inc. (U.S.)
  • Teva Pharmaceutical Industries Ltd. (U.S.)
  • Sumitomo Dainippon Pharma Co. Ltd (Japan)
  • Bausch Health Companies Inc. (Canada)
  • Sanofi (France)
  • Takeda Pharmaceutical Company Limited (Japan)
  • UCB S.A. (China)
  • Marinus Pharmaceuticals Inc. (U.S.)
  • Eisai Co. Ltd (Japan)
  • H. Lundbeck A/S (Denmark)
  • Supernus Pharmaceuticals Inc (U.S.)

Epilepsy Market Scope

The epilepsy market is segmented on the basis of condition, drug, distribution channel and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.


  • Epilepsy Drug Resistant/Intractable Epilepsy
  • Others


  • First-Generation
  • Second-Generation
  • Third-Generation

Distribution Channel

  • Hospitals
  •  Clinics
  • Retail Pharmacies
  • Online Pharmacies

End User

  • Hospitals
  • Clinics
  • Ambulatory Surgical Centers
  • Diagnostic Centers

Investing in this study will provide you with access to valuable information, which includes:

  1. Thorough industry coverage on a global scale, with detailed breakdowns by region.
  2. In-depth analysis of regional markets, encompassing North America, Europe, Asia Pacific, South America, and the Middle East & Africa.
  3. Country-specific market size breakdowns for key countries with significant market shares.
  4. Comprehensive data on market share and revenue/sales from leading industry players.
  5. Examination of market trends, such as emerging technologies, products, and startups, along with PESTEL Analysis, SWOT Analysis, Porter’s Five Forces, and more.
  6. Detailed market size data, including segmentations by application and industry verticals.
  7. Projections and forecasts for the future growth and development of the market.

This Market Intelligence Report Analyses Some of the Most Crucial Concerns:

  1. Anticipated developments in the major segments of the international market in the coming years.
  2. Identification of key players poised to dominate the market in the future.
  3. Assessment of the leading suppliers and producers in this industry.
  4. Examination of growth and expansion strategies implemented by successful industry players.
  5. Insight into sectors expected to experience the most significant demand growth in the near future.
  6. Analysis of the various buyer segments within this market.
  7. Prediction of the regional powerhouse likely to emerge as the dominant player in the international market.
  8. Exploration of the potential impact of a new coronavirus pandemic.
  9. Evaluation of challenges faced by established market players due to the entry of newcomers and strategies to overcome them.

Browse the Comprehensive Research Report Summary with Table of Contents:  https://www.databridgemarketresearch.com/toc/?dbmr=global-epilepsy-market&Shri

Top DBMR Healthcare Reports:        

Global Bipolar Disorder Treatment Market – Industry Trends and Forecast to 2029

Global Diabetic Macular Edema Treatment Market – Industry Trends and Forecast to 2029

Global 3D Cone Beam Computed Tomography (CBCT) Systems Market – Industry Trends and Forecast to 2029

Global Pregnancy Care Products Market – Industry Trends and Forecast to 2029

Global Hair and Care Market – Industry Trends and Forecast to 2030

Global Vascular Stent Market – Industry Trends and Forecast to 2029

About Data Bridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today!

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavours to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data Bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune.

Data Bridge Market Research has over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.

Contact Us:-

Data Bridge Market Research
US: +1 888 387 2818
UK: +44 208 089 1725
Hong Kong: +852 8192 7475

Email:- corporatesales@databridgemarketresearch.com

CDN Newswire